Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 1 5 versus DEXONE 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 1 5 versus DEXONE 4.
DEXONE 1.5 vs DEXONE 4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a long-acting glucocorticoid receptor agonist that suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
Dexamethasone is a long-acting glucocorticoid receptor agonist, binding to glucocorticoid response elements to modulate gene transcription, resulting in anti-inflammatory, immunosuppressive, anti-allergic, and anti-shock effects.
1.5 mg orally once daily
Oral: 0.75–9 mg/day divided every 6–12 hours; IV/IM: 0.5–9 mg/day divided every 6–12 hours.
None Documented
None Documented
Terminal half-life approximately 3-4 hours (dexamethasone), with clinical effects persisting 36-54 hours due to glucocorticoid receptor-mediated actions.
Terminal elimination half-life: 2-3 hours (oral); clinical effects persist longer due to glucocorticoid receptor-mediated genomic actions
Renal (primarily as metabolites, ~60%), biliary/fecal (~30%), with <5% excreted unchanged.
Renal excretion of metabolites (<5% unchanged drug); minor biliary/fecal elimination (<1%)
Category C
Category C
Corticosteroid
Corticosteroid